Modifying the release of gentamicin from microparticles using a PLGA blend

Pharmaceutical Development and Technology

Volumn 7, Issue 2, 2002, Pages 235-248

  Friess, Wolfgang ^a,b   Schlapp, Monika ^a,c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Gentamicin; Microparticles; Molecular weight; Poly(lactic coglycolic acid; Water content

Indexed keywords

GENTAMICIN; POLYGLACTIN; POLYMER; RESOMER;

ARTICLE; DRUG FORMULATION; DRUG RELEASE; HYDROLYSIS; MOLECULAR WEIGHT; PARTICLE SIZE; PRIORITY JOURNAL; VISCOMETRY; WATER CONTENT; WATER PERMEABILITY; WATER TRANSPORT;

GENTAMICINS; LACTIC ACID; MICROSPHERES; MOLECULAR WEIGHT; POLYGLYCOLIC ACID; POLYMERS; SOLUBILITY;

EID: 0036260631     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-120003491     Document Type: Article

References (67)

1. Surgical infection: Current concerns
2. Gentamicin-PMMA: A drug delivered system in treatment of chronic bone soft tissue infections
3. Successful treatment of an infected vascular graft with gentamicin beads
4. Antibiotic containing bone cement beads in the treatment of deep muscle and skeletal infections
5. Local treatment of bone and soft tissue infections with the collagen-gentamicin sponge
6. Bakteriologische und pharmakokinetische aspekte der topischen antibiotikaanwendung
7. Technologische und biochemische aspekte von kollagen-implantaten
8. Biodegradable implants containing gentamicin: Drug release and pharmacokinetics
9. Clinical and pharmacokinetic evaluation of gentamycin containing collagen in groin wound infections after vascular reconstruction
10. Clinical aspects and pharmacokinetics of collagen-gentamicin as adjuvant local therapy of osseous infections
11. Drug carrier systems based on resorbable polyester collagen and/or biomaterial combinations
12. Investigation of the in vitro release of gentamicin from a polyanhydride matrix
13. Controlled release and in vitro antimicrobial activity of gentamicin from the poly-alpha-hydroxy acid films
14. Preparation and characterization of biodegradable poly(L-lactic acid) gentamicin delivery systems
15. Antibiotic in vivo/in vitro release, histocompatibility and biodegradation of gentamicin implants based on lactic acid polymers and copolymers
16. Characterization of soluble salt-loaded, degradable PLGA films and their release of tetracycline
17. Gentamycin/poly(lactic acid) blends aimed at sustained release local antibiotic therapy administered per-operativelyi. I. The case of gentamycin base and gentamycin sulfate in poly(DL-lactic acid) oligomers
18. Gentamycin/poly(lactic acid) blends aimed at sustained release local antibiotic therapy administered per-operatively. II. The case of gentamycin sulfate in high molecular weight poly(DL-lactic acid) and poly(L-lactic acid)
19. Gentamicin-collagen sponge for local applications
20. Comparative investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin
21. Comparison of new and existing spectrophotometric methods for the analysis of tobramycin and other aminoglycosides
22. Biocompatibility: Review of the concept and its relevance to clinical practice
23. Encapsulation of water-soluble drugs by a modified solvent evaporation method. I. Effect of process and formulation variables on drug entrapment
24. A poly(D.L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol
25. The characterization and release kinetics evaluation of baclofen microspheres designed for intrathecal injection
26. Gentamicin
27. In vivo characteristics of low molecular weight copoly(D,L-lactic acid) formulations with controlled release of LH-RH
28. Controlled release of bioactive agents from lactide/glycolide polymers
29. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid
30. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique
31. Development of a single-shot subunit vaccine for HIV-1: Part 4. Optimizing microencapsulation and pulsatile release of MN rgp 120 from biodegradable microspheres
32. In vitro and in vivo evaluation of PLAGA (50/50) microspheres containing 5-fluorouracil prepared by a solvent evaporation method
33. Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation
34. In vivo characteristics of high molecular weight copoly(L-lactide/glycolide) with S-type degradation pattern for application in drug delivery systems
35. Development and characterization of microencapsulated microspheres
36. In vitro and in vivo degradation of double-walled polymer microspheres
37. Compositional and structural analysis of PELA biodegradable block copolymers degrading under in vitro conditions
38. Parenteral depot-systems on the basis of biodegradable polyesters
39. Hydrolytic degradation of films prepared from blends of high and low molecular weight poly(DL-lactic acid)s
40. Characterization of poly(glycolide-co-D,L-lactide)/poly (D,L-lactide) microspheres for controlled release of GM-CSF
41. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres
42. Evaluation of biodegradable poly(lactide) pellets prepared by direct compression
43. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly(D,L-lactic acid-co-glycolic acid) microspheres
44. Importance of the test medium for the release kinetics of a somatostatin analogue from poly(D,L-lactide-co-glycolide) microspheres
45. Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line
46. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: In vitro and in vivo studies with gentamicin and amikacin
47. Factors influencing the release of peptides and proteins from biodegradable depot systems
48. European pharmaceopoeia
49. Process variable implications for residual solvent removal and polymer morphology in the formation of gentamycin loaded poly(L-lactide) microparticles
50. Influence of the preparation method on residual solvents in biodegradable microspheres
51. PDLLA microspheres containing steroids: Spray-drying, o/w and w/o/w emulsifications as preparation methods
52. Mechanisms of solvent evaporation encapsulation processes: Predicting solvent evaporation rate
53. Two poly(D,L-lactide-co-glycolide) 50:50 types: Same polymer but different properties?
54. Release mechanisms from gentamicin loaded microparticles
55. Effects of PLGA end groups on degradation
56. Microencapsulation of antigens using biodegradable polyesters: Facts and phantasies
57. Aliphatic polyesters II. The degradation of poly(DL-lactide), poly(epsilon-caprolactone), and their copolymers in vivo
58. Blends of crystalline and amorphous polylactide. III. Hydrolysis of solution-cast blend films
59. Structure-property relationships in the case of the degradation of massive poly(α-hydroxy acids) in aqueous media. II. Degradation of lactide-glycolide copolymers: PLA37.5GA25 and PLA75GA25
60. Poly(lactide-co-glycolide) decomposition kinetics in vivo and in vitro